Chris@NNW, Author at NetworkNewsWire

WednesdayApr 01, 2026 11:15 am

Soligenix Inc. (NASDAQ: SNGX) Advances Clinical Credibility with HyBryte Research Publication

Publishing research in peer-reviewed journals plays a central role in ensuring the credibility and reliability of scientific findings. Companies that consistently publish their findings often strengthen their credibility with both regulators and the medical community. Most recently, SNGX announced that a clinical summary of its HyBryte(TM) therapy for cutaneous T-cell lymphoma was published in the peer-reviewed journal “Expert Opinion on Investigational Drugs.” The publication of clinical research in peer-reviewed journals remains a critical milestone in drug development, offering independent validation and broader visibility for emerging therapies. Soligenix (NASDAQ: SNGX) recently reached such a milestone with the publication of a clinical…

WednesdayApr 01, 2026 10:30 am

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Expands Strategy for Critical Magnet Materials Supply

Disseminated on behalf of Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) and may include paid advertising. Recent analysis underscores the vulnerability of specialized rare earth elements samarium and gadolinium. This elevated risk profile is largely driven by the dominance of a single country in rare earth production and processing as well as increasing demand for the elements. Ucore is working to accelerate the commercial development of its planned processing capabilities for these materials. Securing reliable supplies of specialized rare earth elements is becoming increasingly important as demand rises across defense, energy and advanced manufacturing sectors. With this in mind,…

WednesdayApr 01, 2026 9:45 am

Perpetuals.com Ltd. (NASDAQ: PDC) to Present AI-Driven Trading Platform at Emerging Growth Conference

The company’s AI-driven digital asset trading platform combines artificial intelligence, blockchain settlement, and EU-compliant market infrastructure, and CEO Patrick Gruhn is expected to outline the company’s strategy and engage with investors at the Emerging Growth Conference, taking place online April 1, 2026. Perpetuals operates technology supporting a CySEC-authorized multilateral trading facility under European regulatory frameworks. Perpetuals.com (NASDAQ: PDC), a fintech company developing AI-powered trading products and prediction markets, announced that CEO Patrick Gruhn will deliver a presentation and participate in a live question-and-answer session with investors at the Emerging Growth Conference on April 1 at 12:35 p.m. Eastern Time. The…

WednesdayApr 01, 2026 9:00 am

Beeline Holdings Inc. (NASDAQ: BLNE) Reports 127% Revenue Growth and Key Milestones Achieved in Q4 2025, Detailing Strategic Priorities for 2026

Beeline Holdings Inc., in a recent update call, reported 127% year-over-year revenue growth for Q4 2025, reflecting the expansion of its digital mortgage platform. Mortgage origination volume rose 44% to $84.7 million during the quarter, and average revenue per loan increased 31%, while cost per loan declined 18%, indicating improving unit economics. Q4 also had the company releasing BeelineEquity, a blockchain-recorded platform allowing homeowners an efficient way to access equity without refinancing. Management says the company ended 2025 debt-free, strengthening its balance sheet ahead of expansion, and executives expect accelerating revenue growth in 2026 as new products and AI-driven automation…

TuesdayMar 31, 2026 11:15 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes

LIXTE’s lead compound, LB-100, is the world’s first and only clinical-stage inhibitor of protein phosphatase 2A (“PP2A”). LB-100 helps in the fight against cancer in a few ways, as it makes cancer cells more sensitive to immunotherapy and chemotherapy, while also disrupting cancer’s internal repair system. The compound has demonstrated a favorable safety profile in Phase 1 clinical trials and has been supported by over 25 published preclinical and translational studies so far. LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor, called LB-100.…

TuesdayMar 31, 2026 10:30 am

GPS-Denied Navigation Isn’t Just a Problem for the Future, It’s Happening Right Now

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising. GPS jamming has emerged as a key modern warfare tactic, using high-powered radio signals to disrupt satellite navigation and shape both offensive operations and defensive countermeasures on the battlefield. This sparks major concern for many organizations and military forces, as several aspects of war rely on GPS, such as tracking, navigation, communication, and others. To fight back against GPS jamming, companies like SPARC AI have created GPS-free technology to deliver real-time insights, detection, and tracking, without having to rely on radar, lidar, and sensors.…

TuesdayMar 31, 2026 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Expands Pipeline Momentum as SGX945 Earns Global Recognition

In the life sciences industry, a robust pipeline is widely recognized as a critical driver of value creation and sustainability. The significance of the UK designation extends beyond a single program. The UK designation builds on additional regulatory recognition for dusquetide, including orphan drug designation from the FDA for Behçet’s disease. A strong and diversified pipeline is often the foundation of long-term success in the biotechnology sector, enabling companies to sustain innovation while advancing multiple therapeutic opportunities. Soligenix (NASDAQ: SNGX) is reinforcing that foundation as its investigational therapy SGX945 receives Promising Innovative Medicine designation in the United Kingdom, a development…

TuesdayMar 31, 2026 9:00 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Is ‘One to Watch’

Cardiovascular disease remains the leading cause of death in the United States, representing a significant and persistent healthcare burden that the company’s solutions are designed to address. Cardio Diagnostics has developed a proprietary platform that integrates epigenetic and genetic biomarkers with artificial intelligence to generate personalized cardiovascular insights from a simple blood sample. The company’s clinical tests are non-invasive, require no fasting or radiation, and are designed to detect and assess coronary heart disease, including forms that may not be identified through traditional diagnostic methods. The company has established multiple commercialization channels, including provider networks, employer partnerships, and community-based programs,…

MondayMar 30, 2026 11:15 am

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Seen as an Easy Way to Capitalize on Gold’s Rare Affordable Price

Disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising. ESGold Corp., a development-stage company committed to the acquisition, exploration, and development of high-quality mineral properties worldwide, continues to demonstrate why gold is a viable investment in 2026. Despite the high volatility of gold and silver over the past year, the ongoing rise of worldwide debt, and its effect on currency and inflation, is expected to continue as a fundamental driver for such tangible assets. The active mining of gold represents both a productive business operation and a high-value end product, a buffer to volatility…

MondayMar 30, 2026 10:30 am

Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) Rare Earth Projects Represent Enhanced Strategic Value Amid Iran Conflict

Disseminated on behalf of  Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising. The conflict involving Iran, with associated tensions between Washington and Beijing, are increasing scrutiny of critical mineral supply chains, particularly rare earth elements (“REEs”). China controls roughly 90% of the world’s processed rare earth supply, giving Beijing significant leverage over global technology and defense manufacturing. Beijing has expanded export controls on several rare earth elements and related technologies, reinforcing its dominance in the supply chain. Western governments are accelerating efforts to build alternative supply sources in North America, with funding and procurement programs emerging…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

Author: Chris@NNW